KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to 34.56%.

  • Resmed's EBIT Margin rose 20100.0% to 34.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.7%, marking a year-over-year increase of 20300.0%. This contributed to the annual value of 32.75% for FY2025, which is 45800.0% up from last year.
  • As of Q4 2025, Resmed's EBIT Margin stood at 34.56%, which was up 20100.0% from 33.43% recorded in Q3 2025.
  • In the past 5 years, Resmed's EBIT Margin ranged from a high of 34.56% in Q4 2025 and a low of 23.66% during Q4 2023
  • Over the past 5 years, Resmed's median EBIT Margin value was 28.99% (recorded in 2021), while the average stood at 29.36%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -34500bps in 2023, then soared by 88900bps in 2024.
  • Quarter analysis of 5 years shows Resmed's EBIT Margin stood at 27.79% in 2021, then decreased by -2bps to 27.1% in 2022, then fell by -13bps to 23.66% in 2023, then skyrocketed by 38bps to 32.54% in 2024, then rose by 6bps to 34.56% in 2025.
  • Its EBIT Margin stands at 34.56% for Q4 2025, versus 33.43% for Q3 2025 and 33.72% for Q2 2025.